Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib
In recent years, there has been increasing pressure on public health systems in high-income countries due to high medicines prices, one of the underlying causes of which are the market monopolies granted to pharmaceutical undertakings. These monopolies have been facilitated by expanded forms of inte...
Saved in:
Main Authors: | Yuanqiong Hu (Author), Dimitri Eynikel (Author), Pascale Boulet (Author), Gaelle Krikorian (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2020-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Brexit - The Consequences for Pharmaceutical Patents and Supplementary Protection Certificates
by: Harry Melville O'Brien, et al.
Published: (2021) -
We Cannot Win the Access to Medicines Struggle Using the Same Thinking That Causes the Chronic Access Crisis
by: Gaëlle Krikorian, et al.
Published: (2020) -
Why we should have more collaboration on HTA in Europe: the example of sofosbuvir
by: Hedi Schelleman, et al.
Published: (2015) -
Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
by: Gabriel Méndez-Valdés, et al.
Published: (2023) -
How Could the Ethical Management of Health Data in the Medical Field Inform Police Use of DNA?
by: Gaelle Krikorian, et al.
Published: (2018)